Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels
Open accessThe DOI matches its Crossref record; 58 of the 61 references it cites were found in a registry or an index.
Abstract
Chemoresistance is a major problem in the therapeutic management of pancreatic cancer, concurring to poor clinical outcome. A number of mechanisms have been proposed to explain resistance to gemcitabine, a standard of care for this malignancy, among which is included aberrant miRNA expression. In the current study, we investigated the role of miR-217, which is strongly down-regulated in cancerous, compared to normal, pancreatic tissues or cells, in sensitizing human pancreatic cancer cell lines to this drug. The low expression of miR-217 in pancreatic cancer patients was confirmed in two gene expression datasets (GSE41372 and GSE60980), and the prognostic value of two target genes (ANLN and TRPS1), was estimated on clinical data from the Tumor Cancer Genome Atlas (TCGA). Transfecting miR-217 mimic in pancreatic cancer cells reduced viability, enhanced apoptosis, and affected cell cycle by promoting a S phase arrest in gemcitabine-treated cells. Moreover, in drug-exposed cells subjected to miR-217 forced expression, a down-regulation for several genes involved in cancer drug resistance was observed, many of which are cell cycle regulators, such as CCND1, CCNE1, CDK2, CDKN1A, CDKN1B, while others, such as ARNT, BRCA1, BRCA2, ELK1, EGFR, ERBB4, and RARA are involved in proliferation and cell cycle progression. Our results support the notion that miR-217 enhances pancreatic cancer sensitivity to gemcitabine, mainly impairing cell cycle progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Consistent with previous reports, GEM induced an S‐phase arrest in both cell lines as well as a G1 arrest in PANC‐1 cells [22, 23] and this was accompanied by increased cyclin A and cyclin B1 levels.”
From Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models (2024) · cites this paper as [23]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Xiao, Y., Deng, T., Su, C., & Shang, Z. (2017) · Oncology Letters · doi:10.3892/ol.2017.6076 · Cited by 49 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundRetractedYin, Z., & Ren, W. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s176618 · Cited by 17 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundRetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“The seventh most common cause of death for cancer worldwide and third in developed countries, pancreatic ductal adenocarcinoma (PDAC) is usually a fatal disease [1], with a 5 year survival rate of around 9% from the time of diagnosis [2].”
BackgroundSwitching from Repression to Activation: MicroRNAs Can Up-Regulate Translation
Vasudevan, S., Tong, Y., & Steitz, J. A. (2007) · Science · doi:10.1126/science.1149460 · Cited by 2,822
Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors
Rawla, P., Sunkara, T., & Gaduputi, V. (2019) · World Journal of Oncology · doi:10.14740/wjon1166 · Cited by 2,269 · cited 1×
“The seventh most common cause of death for cancer worldwide and third in developed countries, pancreatic ductal adenocarcinoma (PDAC) is usually a fatal disease [1], with a 5 year survival rate of around 9% from the time of diagnosis [2].”
BackgroundEpidermal Growth Factor Receptor Cell Proliferation Signaling Pathways
Wee, P., & Wang, Z. (2017) · Cancers · doi:10.3390/cancers9050052 · Cited by 2,027
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584 · cited 1×
“By modulating gene expression, miRNAs influence several biological processes, among which are development, differentiation, proliferation, and apoptosis [17]; when their expression is dysregulated, alterations of such processes may trigger carcinogenesis [18].”
BackgroundMicroRNA-10a binds the 5’UTR of ribosomal protein mRNAs and enhances their translation
Ørom, U. A., Nielsen, F. C., & Lund, A. H. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.05.001 · Cited by 1,384
MicroRNA-373 induces expression of genes with complementary promoter sequences
Place, R. F., Li, L.-C., Pookot, D., Noonan, E. J., & Dahiya, R. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707594105 · Cited by 1,230
Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR
Lytle, J. R., Yario, T. A., & Steitz, J. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703820104 · Cited by 1,196
Yoshida, K., & Miki, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb02195.x · Cited by 753
Szafranska, A. E., Davison, T. S., John, J., Cannon, T., Sipos, B., Maghnouj, A., Labourier, E., & Hahn, S. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210228 · Cited by 664
de Sousa Cavalcante, L., & Monteiro, G. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.041 · Cited by 576
Gemcitabine resistance in pancreatic ductal adenocarcinoma
Binenbaum, Y., Na’ara, S., & Gil, Z. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.10.002 · Cited by 414 · cited 4×
“Gemcitabine is the first line therapy for patients with advanced unresectable PDAC, even though it produces only moderate clinical response since the majority of patients, despite an initial response to therapy, develop chemoresistance over time [6,7,46].”
BackgroundInfluentialMicroRNA‐205–directed transcriptional activation of tumor suppressor genes in prostate cancer
Majid, S., Dar, A. A., Saini, S., Yamamura, S., Hirata, H., Tanaka, Y., Deng, G., & Dahiya, R. (2010) · Cancer · doi:10.1002/cncr.25488 · Cited by 294
miR-24 Regulates Apoptosis by Targeting the Open Reading Frame (ORF) Region of FAF1 in Cancer Cells
Qin, W., Shi, Y., Zhao, B., Yao, C., Jin, L., Ma, J., & Jin, Y. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009429 · Cited by 247
Zhao, W.-G., Yu, S.-N., Lu, Z.-H., Ma, Y.-H., Gu, Y.-M., & Chen, J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq160 · Cited by 237 · cited 2×
“We focused our attention on miR-217, which was shown to be down-regulated in PDAC tissues and cell lines compared to their noncancerous counterpart [24–30] and to function as a tumor suppressor miRNA in PDAC [25,26,29,30].”
BackgroundResultRole of microRNA in anticancer drug resistance
Zheng, T., Wang, J., Chen, X., & Liu, L. (2010) · International Journal of Cancer · doi:10.1002/ijc.24782 · Cited by 233 · cited 3×
“The latter aspect is gaining increasing attention in recent years, since more and more miRNAs are being found to either enhance or decrease sensitivity of cancer cells to different chemotherapeutics [19,20].”
BackgroundThe Role of MicroRNAs in Biological Processes
Tüfekci, K. U., Meuwissen, R. L. J., & Genç, Ş. (2014) · Methods in Molecular Biology · doi:10.1007/978-1-62703-748-8_2 · Cited by 195 · cited 1×
“By modulating gene expression, miRNAs influence several biological processes, among which are development, differentiation, proliferation, and apoptosis [17]; when their expression is dysregulated, alterations of such processes may trigger carcinogenesis [18].”
BackgroundBiliran, H., Wang, Y., Banerjee, S., Xu, H., Heng, H., Thakur, A., Bollig, A., Sarkar, F. H., & Liao, J. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2419 · Cited by 181 · cited 1×
“Over-expression of Cyclin D1 was found to confer gemcitabine and cisplatin resistance to pancreatic cancer cell [49]; CCNE1, CDK2, and CDKN1A, previously reported to be up-regulated by gemcitabine as confirmed in our study, were also implied in chemotherapy resistance [50,51].”
BackgroundGemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
Kim, M. P., & Gallick, G. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2247 · Cited by 177 · cited 1×
“Gemcitabine is the first line therapy for patients with advanced unresectable PDAC, even though it produces only moderate clinical response since the majority of patients, despite an initial response to therapy, develop chemoresistance over time [6,7,46].”
BackgroundPromising molecular mechanisms responsible for gemcitabine resistance in cancer
Jia, Y., & Xie, J. (2015) · Genes & Diseases · doi:10.1016/j.gendis.2015.07.003 · Cited by 170 · cited 4×
“Gemcitabine is the first line therapy for patients with advanced unresectable PDAC, even though it produces only moderate clinical response since the majority of patients, despite an initial response to therapy, develop chemoresistance over time [6,7,46].”
BackgroundInfluentialMoretti, F., Thermann, R., & Hentze, M. W. (2010) · RNA · doi:10.1261/rna.2384610 · Cited by 166
The code within the code: microRNAs target coding regions
Forman, J. J., & Coller, H. A. (2010) · Cell Cycle · doi:10.4161/cc.9.8.11202 · Cited by 154
Shi, Z., Azuma, A., Sampath, D., Li, Y., Huang, P., & Plunkett, W. K. (2001) · PubMed · Cited by 139
Ciliberto, D., Botta, C., Correale, P., Rossi, M., Caraglia, M., Tassone, P., & Tagliaferri, P. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2012.08.019 · Cited by 138 · cited 1×
“Due to the lack of early specific symptoms and late diagnosis, surgery is a valid curative option in only 15 to 20% of PDAC carriers [3], while for the remaining patients gemcitabine-based chemotherapy represents the mainstay treatment [4].”
BackgroundIdichi, T., Seki, N., Kurahara, H., Yonemori, K., Osako, Y., Arai, T., Okato, A., Kita, Y., Arigami, T., Mataki, Y., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18261 · Cited by 104 · cited 2×
“We focused our attention on miR-217, which was shown to be down-regulated in PDAC tissues and cell lines compared to their noncancerous counterpart [24–30] and to function as a tumor suppressor miRNA in PDAC [25,26,29,30].”
BackgroundResultThe Role of MicroRNAs in Chemoresistance
Bahreini, F., & Rezaei, N. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_336-1 · Cited by 100
Peran, I., Madhavan, S., Byers, S. W., & McCoy, M. D. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0290 · Cited by 95 · cited 1×
“[37], samples of various origin and (pseudo)- normal samples were excluded.”
BackgroundD’Aronzo, M., Vinciguerra, M., Mazza, T., Panebianco, C., Saracino, C., Pereira, S. P., Graziano, P., & Pazienza, V. (2015) · Oncotarget · doi:10.18632/oncotarget.4186 · Cited by 87
Self-citationMicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions
Hernandez, Y. G. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i1.18 · Cited by 80
Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro
Pauwels, B., Korst, A. E. C., Pattyn, G. G. O., Lambrechts, H. A. J., Bockstaele, D. R. V., Vermeulen, K., Lenjou, M., de Pooter, C. M. J., Vermorken, J. B., & Lardon, F. (2003) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(03)01443-3 · Cited by 76
Wang, H., Qin, R., Guan, A., Yao, Y., Huang, Y., Jia, H., Huang, W., & Gao, J. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26901 · Cited by 74 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundVychytilova-Faltejskova, P., Kiss, I., Klusova, S., Hlavsa, J., Prochazka, V., Kala, Z., Mazanec, J., Hausnerova, J., Kren, L., Hermanova, M., et al. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0272-6 · Cited by 72
Role of microRNAs in chemoresistance.
Magee, P., Shi, L., & Garofalo, M. (2015) · PubMed · doi:10.3978/j.issn.2305-5839.2015.11.32 · Cited by 70 · cited 3×
“The latter aspect is gaining increasing attention in recent years, since more and more miRNAs are being found to either enhance or decrease sensitivity of cancer cells to different chemotherapeutics [19,20].”
BackgroundHamed, S. S., Straubinger, R. M., & Jusko, W. J. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2226-6 · Cited by 65 · cited 1×
“Gemcitabine, as a nucleoside analog, exerts its cytotoxicity on cells in S phase, that is why an initial low dose, which synchronizes cells in S phase, would sensitize them to further administrations [47].”
BackgroundNishioka, C., Ikezoe, T., Yang, J., Nobumoto, A., Tsuda, M., & Yokoyama, A. (2013) · Cancer Science · doi:10.1111/cas.12339 · Cited by 65 · cited 2×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundGuo, J., Feng, Z., Huang, Z., Wang, H., & Lu, W. (2014) · Molecules and Cells · doi:10.14348/molcells.2014.0121 · Cited by 63 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundSIRT1-metabolite binding histone macroH2A1.1 protects hepatocytes against lipid accumulation
Pazienza, V., Borghesan, M., Mazza, T., Sheedfar, F., Panebianco, C., Williams, R., Mazzoccoli, G., Andriulli, A., Nakanishi, T., & Vinciguerra, M. (2014) · Aging · doi:10.18632/aging.100632 · Cited by 61 · cited 1×
“The effects of the miR-217 over-expression and gemcitabine treatment on cell cycle distribution of overnight serum deprived synchronized pancreatic cancer cells were assessed by flow cytometric analysis using the Muse Cell Cycle kit (Merck Millipore, Milan Italy) at the Muse Cell Analyzer, as previously described [38,…”
MethodSelf-citationStarr, A., Greif, J., Vexler, A. M., Ashkenazy‐Voghera, M., Gladesh, V., Rubin, C., Kerber, G., Marmor, S., Lev‐Ari, S., Inbar, M., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21818 · Cited by 59
Montano, R. E., Khan, N. I., Hou, H. G., Seigne, J. D., Ernstoff, M. S., Lewis, L. D., & Eastman, A. R. (2017) · Oncotarget · doi:10.18632/oncotarget.18834 · Cited by 53
MicroRNA Mechanisms of Action: What have We Learned from Mice?
Jin, H. Y., & Xiao, C. (2015) · Frontiers in Genetics · doi:10.3389/fgene.2015.00328 · Cited by 50
Shin, S. Y., Kim, C. G., Lim, Y., & Lee, Y. H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.216721 · Cited by 46
Yang, J., Hf, Z., & Cf, Q. (2017) · PubMed · Cited by 39
Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells
Kolesar (2010) · International Journal of Oncology · doi:10.3892/ijo.2010.866 · Cited by 36 · cited 1×
“Over-expression of Cyclin D1 was found to confer gemcitabine and cisplatin resistance to pancreatic cancer cell [49]; CCNE1, CDK2, and CDKN1A, previously reported to be up-regulated by gemcitabine as confirmed in our study, were also implied in chemotherapy resistance [50,51].”
BackgroundMiao, X., Koch, G., Ait‐Oudhia, S., Straubinger, R. M., & Jusko, W. J. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00421 · Cited by 36
Azevedo‐Pouly, A. C. P., Sutaria, D. S., Jiang, J., Elgamal, O. A., Amari, F., Allard, D., Grippo, P. J., Coppola, V., & Schmittgen, T. D. (2016) · Functional & Integrative Genomics · doi:10.1007/s10142-016-0512-1 · Cited by 35
Wald, P., Liu, X. S., Pettit, C. J., Dillhoff, M. E., Manilchuk, A., Schmidt, C. R., Wuthrick, E. J., Chen, W., & Williams, T. M. (2017) · Oncotarget · doi:10.18632/oncotarget.20277 · Cited by 33
Chen, Q., Wang, P., Fu, Y., Liu, X., Xu, W., Wei, J., Gao, W., Jiang, K., Wu, J., & Miao, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.6036 · Cited by 26 · cited 2×
“We focused our attention on miR-217, which was shown to be down-regulated in PDAC tissues and cell lines compared to their noncancerous counterpart [24–30] and to function as a tumor suppressor miRNA in PDAC [25,26,29,30].”
BackgroundAntitumor activity of gemcitabine against high-grade meningiomain vitroandin vivo
Takeda, H., Okada, M., Kuramoto, K., Suzuki, S., Sakaki, H., Sanomachi, T., Seino, S., Yoshioka, T., Hirano, H., Arita, K., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18827 · Cited by 26
Kim, Y., Kim, H., Park, D., 한민호, Lee, Y. S., Lee, Y. S., Choe, J., Kim, Y. M., & Jeoung, D. (2016) · Oncotarget · doi:10.18632/oncotarget.7185 · Cited by 24 · cited 2×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
BackgroundPan, B., Yang, J., Wang, X., Xu, K., & Ikezoe, T. (2018) · Experimental Hematology · doi:10.1016/j.exphem.2018.09.001 · Cited by 24
Wang, X., Dasari, S., Nowakowski, G. S., Lazaridis, K. N., Wieben, E. D., Kadin, M. E., Feldman, A. L., & Boddicker, R. L. (2017) · Oncotarget · doi:10.18632/oncotarget.15441 · Cited by 24
Gardella, K. A., Muro, I., Fang, G., Sarkar, K., Méndez-Solís, O., & Wright, C. W. (2016) · Oncotarget · doi:10.18632/oncotarget.7539 · Cited by 23
Ren, L., & Yu, Y. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s154226 · Cited by 19
Management of Locally Advanced Pancreatic Cancer
Martin, R. C. G. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.010 · Cited by 17
Attenuation of hedgehog/GLI signaling by NT1721 extends survival in pancreatic cancer
Kowolik, C. M., Lin, M., Xie, J., Overman, L. E., & Horne, D. A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1445-z · Cited by 6 · cited 1×
“Over-expression of Cyclin D1 was found to confer gemcitabine and cisplatin resistance to pancreatic cancer cell [49]; CCNE1, CDK2, and CDKN1A, previously reported to be up-regulated by gemcitabine as confirmed in our study, were also implied in chemotherapy resistance [50,51].”
BackgroundMir-217 Reverses the TKI Drug-Resistance of K562 Cells By the Downregulation of Heme Oxygenase-1
Wang, J., Wang, C., Ma, D., Fang, Q., & Ren, M. R. (2015) · Blood · doi:10.1182/blood.v126.23.5138.5138 · Cited by 2 · cited 3×
“It is known that miR-217 levels are inversely correlated with resistance to several chemotherapeutics [40,41] and that its ectopic expression increases sensitivity of lung and cervical cancer cells to cisplatin [31,36], of leukemia cells to doxorubicin, imatinib [33,34], and dasatinib [35], and of gastric cancer cells…”
Background
Cited by
Xia, W., Chen, W., Ni, C., Meng, X., Wu, J., Yang, Q., Tang, H., Yuan, H., & Shan, F. (2023) · Breast Cancer Research · doi:10.1186/s13058-023-01672-x · Cited by 52
Bravo-Vázquez, L. A., Frías-Reid, N., Ramos-Delgado, A. G., Osorio-Pérez, S. M., Zlotnik-Chávez, H. R., Pathak, S., Banerjee, A., Bandyopadhyay, A., Duttaroy, A. K., & Paul, S. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101579 · Cited by 40
“miR-217 Downregulated – Induced miR-217 expression enhances gemcitabine sensitivity [132]”
BackgroundMicroRNA-217 modulates pancreatic cancer progression via targeting ATAD2
Dutta, M., Das, B., Mohapatra, D., Behera, P., Senapati, S., & Roychowdhury, A. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120592 · Cited by 29
Yang, L., Gong, X., Wang, J., Fan, Q., Yuan, J., Yang, X., Sun, X., Li, Y., & Wang, Y. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.154022 · Cited by 27
Wu, R., Su, Z., Le, Z., Pei, R., Ding, Y., Li, D., Zhu, S., Xu, L., Zhao, W., & Zhou, W. (2023) · Stem Cells International · doi:10.1155/2023/6510571 · Cited by 18
Metadata
- Authors
- Panebianco, C., Trivieri, N., Villani, A., Terracciano, F., Latiano, T. P., Potenza, A., Perri, F., Binda, E., & Pazienza, V.
- Affiliations
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Binda, Elena
- Pazienza, Valerio
- ORCID
- Venue
- Biomolecules
- Publisher
- MDPI AG
- Published
- 2021-04-26
- Volume
- 11
- Issue
- 5
- Pages
- 639
- ISSN
- 2218-273X (ISSN-L)
- PMC
- PMC8146031
- OpenAlex
- W3158790987
- Cited by
- 26
- References
- 61
- Citations by year
- 2026: 4 · 2025: 4 · 2024: 6 · 2023: 6 · 2022: 5 · 2021: 1
- FWCI
- 1.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Biomolecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Ministero della Salute (Ricerca Corrente 2018-2020)
- Associazione Italiana per la Ricerca sul Cancro (IG2019-ID23006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- miR-217, gemcitabine, pancreatic cancer, chemoresistance, microRNA restoration, cell cycle arrest, S phase arrest, apoptosis, anillin, TRPS1, cell cycle regulators, drug sensitivity
- MeSH terms
- Gemcitabine, Cell Survival, Deoxycytidine, Humans, Pancreatic Neoplasms, Prognosis, Apoptosis, Cell Cycle Proteins, Drug Resistance, Neoplasm, Databases, Genetic, MicroRNAs, Cell Line, Tumor, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.